Disrupt Conventional Medicine

---

With our manufacturing breakthrough, we’ve developed a nanolithographic process to fabricate stable LNPs via controlling the architecture shape, size, and surface chemistry resulting in lower toxicity, higher efficacy, simpler logistics, and an in-vivo outpatient experience. With EnsaliX’s capability in predicting optimal nanomedicine formulations in terms of safety, stability, and selectivity, we’re able to discover new candidates quickly with high confidence of clinical success in a cost- effective manner to develop affordable gene therapies.